In a meta-analysis study that contrasted aromatase inhibitors with clomiphene citrate, there were statistically significant results in favor of aromatase inhibitors as it has a higher number of pregnancies and live births [36]. According to a recent systematic review and meta-analysis of studies on ovulation induction, letrozole is superior to clomiphene citrate in terms of the greater number of ovulation rate, pregnancy, and live birth for WHO Group 2 (including PCOS) anovulatory females, as well as for pregnancy rate in therapy [37]. Here, CYP19A1 is linked to polycystic ovary syndrome.